Company intelligence / Profile preview

Venus Concept

Toronto, Ontario, Canadavenus.ai ↗

Ownership: Public · VERO
Employees: ~292
Development stage: Other

Overview

Venus Concept develops and markets minimally invasive and non-invasive medical aesthetic devices for skin tightening, body contouring, wrinkle/cellulite/fat reduction, facial resurfacing/remodeling as well as robotic systems for surgical/non-surgical hair restoration. Its products are FDA-cleared/CE-marked where required and used globally in dermatology clinics/plastic surgery practices/medical spas. The company’s technologies are widely adopted with over ten million treatments performed worldwide annually. Financially active on NASDAQ under symbol VERO with recent revenues reported at $64.8M in FY2024.

Therapeutic areas: OtherDermatologyMetabolic Disorders
Modalities: Device (energy-based aesthetic devices)Robotic system (for hair restoration)Non-pharmacological therapy (aesthetic procedures)
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Venus Concept.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Venus Concept.